Ovarian expression of functional MTTP and apoB for VLDL assembly and secretion in chickens.

Poult Sci

Department of Animal Science, National Chung Hsing University, Taichung 40227, Taiwan; The iEGG and Animal Biotechnology Center and Rong Hsing Research Center for Translational Medicine, National Chung Hsing University, Taichung 40227, Taiwan; i-Center for Advanced Science and Technology (iCAST), National Chung Hsing University, Taichung 40227, Taiwan. Electronic address:

Published: March 2025

In mammals, tissues other than liver and intestine are known to possess functional MTTP (microsomal triglyceride transfer protein) and apoB (apolipoprotein B) capable of VLDL (very low-density lipoprotein) assembly. Birds are oviparous and possess unique capabilities in lipid biology to accommodate yolk formation through massive deposition of hepatically assembled yolk-targeted VLDLy into ovarian follicles. Following identifications of MTTP and ApoB expression within chicken ovarian stroma, granulosa, theca, and epithelial cells of various classes of follicles, we sought to define the functionality of ovarian MTTP and ApoB in VLDL assembly. In situ hybridization analysis found that ApoB transcripts are most abundant in thecal layers, whereas immunohistochemistry showed that MTTP predominates in the granulosa layers. MTTP lipid transfer activity was greater in small yellow follicles than in hierarchical follicles. Metabolic labeling, electron microscopy, and Western blot studies confirmed the functionality of ovarian apoB and MTTP as newly assembled VLDL around 50-200 nm in diameter and lacking ApoVLDL-II dissimilar to VLDLy, were secreted from cultured follicular cells. Lomitapide and the ApoB-antisense oligonucleotide Mipomersen dose-dependently decreased MTTP activity and VLDL-apoB secretion from cultured follicular cells, while oleate addition or acute heat stress enhanced VLDL-apoB secretion. Ultrastructural images showed VLDL assembly and trafficking toward the secretion route. The findings support the notion that VLDL assembly and secretion within avian ovarian tissues functions as a protective mechanism against fuel and physical stressors to secure follicle development and/or nutritional quality control of yolk for embryo development.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.psj.2025.104993DOI Listing

Publication Analysis

Top Keywords

vldl assembly
16
mttp apob
12
mttp
8
functional mttp
8
apob vldl
8
assembly secretion
8
functionality ovarian
8
cultured follicular
8
follicular cells
8
vldl-apob secretion
8

Similar Publications

Ovarian expression of functional MTTP and apoB for VLDL assembly and secretion in chickens.

Poult Sci

March 2025

Department of Animal Science, National Chung Hsing University, Taichung 40227, Taiwan; The iEGG and Animal Biotechnology Center and Rong Hsing Research Center for Translational Medicine, National Chung Hsing University, Taichung 40227, Taiwan; i-Center for Advanced Science and Technology (iCAST), National Chung Hsing University, Taichung 40227, Taiwan. Electronic address:

In mammals, tissues other than liver and intestine are known to possess functional MTTP (microsomal triglyceride transfer protein) and apoB (apolipoprotein B) capable of VLDL (very low-density lipoprotein) assembly. Birds are oviparous and possess unique capabilities in lipid biology to accommodate yolk formation through massive deposition of hepatically assembled yolk-targeted VLDLy into ovarian follicles. Following identifications of MTTP and ApoB expression within chicken ovarian stroma, granulosa, theca, and epithelial cells of various classes of follicles, we sought to define the functionality of ovarian MTTP and ApoB in VLDL assembly.

View Article and Find Full Text PDF

During the periparturient transition period, dairy cows are often accompanied by disorders of liver glycolipid metabolism. The PI3K/AKT signaling pathway plays an important role in the homeostasis of glycolipid metabolism. Trivalent chromium [Cr(III)] is an essential trace element in the body.

View Article and Find Full Text PDF

Lomitapide: navigating cardiovascular challenges with innovative therapies.

Mol Biol Rep

October 2024

College of Dental Medicine, Lincoln Memorial University, LMU tower, 1705 St. Mary Street, Knoxville, TN, 37917, USA.

Article Synopsis
  • Dyslipidemia is a key risk factor for cardiovascular diseases, and current treatments primarily aim to lower LDL cholesterol levels to prevent conditions like atherosclerosis and myocardial infarction.
  • Homozygous Familial Hypercholesterolemia (HoFH) results from mutations in the LDL receptor, leading to very high LDL cholesterol levels, which often do not respond well to standard statin therapy.
  • Lomitapide, a microsomal triglyceride transfer protein inhibitor, has been approved for HoFH treatment; it effectively lowers LDL-C levels without affecting the LDL receptor and has been shown to reduce LDL-C by more than 50% in resistant cases.
View Article and Find Full Text PDF

FITM2 deficiency results in ER lipid accumulation, ER stress, and reduced apolipoprotein B lipidation and VLDL triglyceride secretion in vitro and in mouse liver.

Mol Metab

December 2024

Department of Medicine (Cardiology), the Cardiovascular Research Center, and the Marc and Ruti Bell Program in Vascular Biology, NYU Grossman School of Medicine, NY, USA. Electronic address:

Objective: Triglycerides (TGs) associate with apolipoprotein B100 (apoB100) to form very low density lipoproteins (VLDLs) in the liver. The repertoire of factors that facilitate this association is incompletely understood. FITM2, an integral endoplasmic reticulum (ER) protein, was originally discovered as a factor participating in cytosolic lipid droplet (LD) biogenesis in tissues that do not form VLDL.

View Article and Find Full Text PDF

Molecular Regulation and Therapeutic Targeting of VLDL Production in Cardiometabolic Disease.

Cell Mol Gastroenterol Hepatol

December 2024

Division of Gastroenterology, Department of Medicine, Washington University School of Medicine, Saint Louis, Missouri. Electronic address:

There exists a complex relationship between steatotic liver disease (SLD) and atherosclerotic cardiovascular disease (CVD). CVD is a leading cause of morbidity and mortality among individuals with SLD, particularly those with metabolic dysfunction-associated SLD (MASLD), a significant proportion of whom also exhibit features of insulin resistance. Recent evidence supports an expanded role of very low-density lipoprotein (VLDL) in the pathogenesis of CVD in patients, both with and without associated metabolic dysfunction.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!